Authors:
Boyce, S
Smith, D
Carlson, E
Hewson, L
Rigby, M
O'Donnell, R
Harrison, T
Rupniak, NMJ
Citation: S. Boyce et al., Intra-amygdala injection of the substance P (NK1 receptor) antagonist L-760735 inhibits neonatal vocalisations in guinea-pigs, NEUROPHARM, 41(1), 2001, pp. 130-137
Authors:
Boyce, S
Rupniak, NMJ
Steventon, MJ
Iversen, SD
Citation: S. Boyce et al., Differential effects of D-1 and D-2 agonists in MPTP,treated primates: Functional implications for Parkinson's disease, NEUROLOGY, 57(10), 2001, pp. S27-S33
Authors:
Harrison, T
Owens, AP
Williams, BJ
Swain, CJ
Williams, A
Carlson, EJ
Rycroft, W
Tattersall, FD
Cascieri, MA
Chicchi, GG
Sadowski, S
Rupniak, NMJ
Hargreaves, RJ
Citation: T. Harrison et al., An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration, J MED CHEM, 44(24), 2001, pp. 4296-4299
Authors:
Cheeta, S
Tucci, S
Sandhu, J
Williams, AR
Rupniak, NMJ
File, SE
Citation: S. Cheeta et al., Anxiolytic actions of the substance P (NK1) receptor antagonist L-760735 and the 5-HT1A agonist 8-OH-DPAT in the social interaction test in gerbils, BRAIN RES, 915(2), 2001, pp. 170-175
Authors:
Rupniak, NMJ
Carlson, EC
Harrison, T
Oates, B
Seward, E
Owen, S
de Felipe, C
Hunt, S
Wheeldon, A
Citation: Nmj. Rupniak et al., Pharmacological blockade or genetic deletion of substance P (NK1) receptors attenuates neonatal vocalisation in guinea-pigs and mice, NEUROPHARM, 39(8), 2000, pp. 1413-1421
Authors:
Hale, JJ
Mills, SG
MacCoss, M
Dorn, CP
Finke, PE
Budhu, RJ
Reamer, RA
Huskey, SEW
Luffer-Atlas, D
Dean, BJ
McGowan, EM
Feeney, WP
Chiu, SHL
Cascieri, MA
Chicchi, GG
Kurtz, MM
Sadowski, S
Ber, E
Tattersall, FD
Rupniak, NMJ
Williams, AR
Rycroft, W
Hargreaves, R
Metzger, JM
MacIntyre, DE
Citation: Jj. Hale et al., Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs, J MED CHEM, 43(6), 2000, pp. 1234-1241
Citation: Nmj. Rupniak et Ms. Kramer, Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK1) antagonists, TRENDS PHAR, 20(12), 1999, pp. 485-490
Authors:
Boyce, S
Wyatt, A
Webb, JK
O'Donnell, R
Mason, G
Rigby, M
Sirinathsinghji, D
Hill, RG
Rupniak, NMJ
Citation: S. Boyce et al., Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn, NEUROPHARM, 38(5), 1999, pp. 611-623
Authors:
Boyce, S
Webb, JK
Carlson, E
Rupniak, NMJ
Hill, RG
Martin, JE
Citation: S. Boyce et al., Onset and progression of motor deficits in motor neuron degeneration (mnd)mice are unaltered by the glycine/NMDA receptor antagonist L-701,324 or the MAO-B inhibitor R(-)-deprenyl, EXP NEUROL, 155(1), 1999, pp. 49-58
Authors:
Smith, DW
Hewson, L
Fuller, P
Williams, AR
Wheeldon, A
Rupniak, NMJ
Citation: Dw. Smith et al., The substance P antagonist L-760,735 inhibits stress-induced NK, receptor internalisation in the basolateral amygdala, BRAIN RES, 848(1-2), 1999, pp. 90-95
Authors:
Cumberbatch, MJ
Carlson, E
Wyatt, A
Boyce, S
Hill, RG
Rupniak, NMJ
Citation: Mj. Cumberbatch et al., Reversal of behavioural and electrophysiological correlates of experimental peripheral neuropathy by the NK1 receptor antagonist GR205171 in rats, NEUROPHARM, 37(12), 1998, pp. 1535-1543